SCHEMBL6640901

SCHEMBL6640901

O=Cc1cc(C=CC(=O)O)ccc1O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.68
HSD17B10 Q99714 4/20 0.68
CA1 P00915 4/20 0.68
CA2 P00918 4/20 0.68
CA4 P22748 4/20 0.68
CA12 O43570 3/20 0.68
CA3 P07451 3/20 0.68
CA6 P23280 3/20 0.68
CA5A P35218 3/20 0.68
CA7 P43166 3/20 0.68
CA9 Q16790 3/20 0.68
CA14 Q9ULX7 3/20 0.68
CA5B Q9Y2D0 3/20 0.68
AKR1B10 O60218 3/20 0.68
AKR1B1 P15121 3/20 0.68
DPP4 P27487 2/20 0.68
NFKB1 P19838 2/20 0.68
ALDH1A1 P00352 2/20 0.68
HPGD P15428 2/20 0.68
MAPK1 P28482 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6644081 1.00 KDM4E (0.68) KDM4EHSD17B10CA1CA2CA4
SCHEMBL3422777 0.89 KDM4E (0.72) KDM4EHSD17B10CA1CA2CA4
SCHEMBL3422778 0.89 KDM4E (0.72) KDM4EHSD17B10CA1CA2CA4
SCHEMBL27436614 0.85 KDM4E (0.56) KDM4EHSD17B10CA1CA2CA4
SCHEMBL6638484 0.84 PELI1 (0.68) KDM4EHSD17B10CA1CA2CA4
SCHEMBL19454449 0.84 BACE1 (0.62) KDM4EHSD17B10CA1CA2CA4
SCHEMBL25705683 0.83 BACE1 (0.58) KDM4EHSD17B10CA1CA2CA4
Caffeic Acid SCHEMBL7088868 0.82 KDM4E (0.86) KDM4EHSD17B10CA1CA2CA4
Caffeic Acid SCHEMBL1262229 0.81 KDM4E (1.00) KDM4EHSD17B10CA1CA2CA4
Caffeic Acid SCHEMBL23358 0.81 KDM4E (1.00) KDM4EHSD17B10CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1412327-A2 INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE LG Biomedical Institute (US) 2004-04-28 EP claimed
US-20030208067-A1 Inhibitors of protein kinase for the treatment of disease LG BIOMEDICAL INSTITUTE 2003-11-06 US claimed
WO-2002096867-A2 INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE LG BIOMEDICAL INSTITUTE (US) 2002-12-05 WO claimed
US-11970448-B2 Monomers capable of dimerizing in an aqueous solution, and methods of using same CORNELL UNIVERSITY (US) 2024-04-30 US disclosed
EP-4346810-A1 COMPOSITIONS FOR REGULATING HOMEOSTASIS OF CORTISOL AND IMPROVING SLEEP QUALITY AND METHODS OF USE AND PRODUCTION THEREOF Unigen, Inc. (US) 2024-04-10 EP disclosed
CN-117794534-A Compositions for modulating cortisol homeostasis and improving sleep quality and methods of use and preparation thereof 尤尼根公司 2024-03-29 CN disclosed
US-20220387366-A1 Compositions for Regulating Homeostasis of Cortisol and Improving Sleep Quality and Methods of Use and Production Thereof UNIGEN, INC. (US) 2022-12-08 US disclosed
WO-2022256624-A1 COMPOSITIONS FOR REGULATING HOMEOSTASIS OF CORTISOL AND IMPROVING SLEEP QUALITY AND METHODS OF USE AND PRODUCTION THEREOF UNIGEN, INC. (US) 2022-12-08 WO disclosed
US-20200354319-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME UNIV CORNELL (US) 2020-11-12 US disclosed
US-20140194383-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CORNELL UNIVERSITY (US) 2014-07-10 US disclosed
EP-2694707-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME Cornell University (US) 2014-02-12 EP disclosed
WO-2013058824-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CORNELL UNIVERSITY (US) 2013-04-25 WO disclosed
EP-1412327-A2 INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE LG Biomedical Institute (US) 2004-04-28 EP disclosed
US-20030208067-A1 Inhibitors of protein kinase for the treatment of disease LG BIOMEDICAL INSTITUTE 2003-11-06 US disclosed
US-20030187007-A1 Inhibitors of protein kinase for the treatment of disease LG BIOMEDICAL INSTITUTE 2003-10-02 US disclosed
WO-2002096867-A2 INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE LG BIOMEDICAL INSTITUTE (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11970448-B2 Monomers capable of dimerizing in an aqueous solution, and methods of using same CALCOCO2, MDN1, MBNL1 KDM4E 4611/4885HSD17B10 4404/4885CA1 1922/4885
US-20030208067-A1 Inhibitors of protein kinase for the treatment of disease MAP3K20, MAP3K1, MAP3K2 KDM4E 1458/4885HSD17B10 879/4885CA1 4632/4885
US-20030187007-A1 Inhibitors of protein kinase for the treatment of disease MAP3K20, MAP3K1, MAP3K2 KDM4E 1458/4885HSD17B10 879/4885CA1 4632/4885
US-20200354319-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CALCOCO2, MDN1, MBNL1 KDM4E 4611/4885HSD17B10 4404/4885CA1 1922/4885
US-20140194383-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CALCOCO2, MDN1, MBNL1 KDM4E 4611/4885HSD17B10 4404/4885CA1 1922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.